How does ANR's PB Ratio compare to its peers?

ANR is expensive based on its Price-To-Book Ratio (8.2x) compared to the peer average (1.7x).

How does ANR's PB Ratio compare vs other companies in the AU Biotechs Industry?

ANR is expensive based on its Price-To-Book Ratio (8.2x) compared to the Australian Biotechs industry average (3.1x).

What is ANR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate ANR's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of ANR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate ANR's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Anatara Lifesciences (ASX:ANR) - Stock Price, News & Analysis

ANR Stock Overview

Engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. More details

ANR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings have grown 11.4% per year over the past 5 years

Risk Analysis

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap (A$11M)

Makes less than USD$1m in revenue (A$0)

Volatile share price over the past 3 months compared to the Australian market

Anatara Lifesciences Ltd Competitors

Chimeric Therapeutics

ASX:CHM

AU$8.1m

NeuroScientific Biopharmaceuticals

ASX:NSB

AU$5.4m

Tissue Repair

ASX:TRP

AU$15.7m

Prescient Therapeutics

ASX:PTX

AU$30.6m

Price History & Performance

Summary of all time highs, changes and price drops for Anatara Lifesciences
Historical stock prices
Current Share Price	AU$0.058
52 Week High	AU$0.073
52 Week Low	AU$0.021
Beta	0.81
11 Month Change	-3.33%
3 Month Change	20.83%
1 Year Change	107.14%
33 Year Change	-58.57%
5 Year Change	-71.00%
Change since IPO	-86.19%

Recent updates

Shareholder Returns

	ANR	AU Biotechs	AU Market
7D	-9.4%	-3.8%	0.9%
1Y	107.1%	9.9%	17.7%

Return vs Industry: ANR exceeded the Australian Biotechs industry which returned 10% over the past year.

Return vs Market: ANR exceeded the Australian Market which returned 17.2% over the past year.

Price Volatility

Is ANR's price volatile compared to industry and market?
ANR volatility
ANR Average Weekly Movement	13.7%
Biotechs Industry Average Movement	9.9%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.2%
10% least volatile stocks in AU Market	3.3%

Stable Share Price: ANR's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: ANR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

Founded	Employees	CEO	Website
2010	n/a	David Brookes	anataralifesciences.com

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. The company offers Gastrointestinal ReProgramming, a proprietary formulation to address irritable bowel syndrome. It also provides Detach for the treatment of diarrhea disease in piglets.

Anatara Lifesciences Ltd Fundamentals Summary

How do Anatara Lifesciences's earnings and revenue compare to its market cap?
ANR fundamental statistics
Market cap	AU$11.19m
Earnings (TTM)	-AU$1.45m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-7.7x

P/E Ratio

Is ANR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ANR income statement (TTM)
Revenue	AU$0
Cost of Revenue	AU$748.91k
Gross Profit	-AU$748.91k
Other Expenses	AU$702.33k
Earnings	-AU$1.45m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0075
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ANR perform over the long term?

See historical performance and comparison

ANR Stock Overview

Rewards

Risk Analysis

Anatara Lifesciences Ltd Competitors

ASX:CHM

AU$8.1m

ASX:NSB

AU$5.4m

ASX:TRP

AU$15.7m

ASX:PTX

AU$30.6m

Price History & Performance

Recent News & Updates

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.5 million.

Anatara Lifesciences Ltd, Annual General Meeting, Nov 14, 2024

New major risk - Share price stability

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1 million.

New major risk - Shareholder dilution

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million.

Recent updates

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.5 million.

Anatara Lifesciences Ltd, Annual General Meeting, Nov 14, 2024

New major risk - Share price stability

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1 million.

New major risk - Shareholder dilution

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million.

New major risk - Share price stability

New major risk - Shareholder dilution

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.315185 million.

New major risk - Shareholder dilution

No independent directors

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

Anatara Lifesciences Ltd, Annual General Meeting, Nov 10, 2023

Less than half of directors are independent

Anatara Lifesciences Ltd Announces board Changes

Insufficient new directors

Anatara Lifesciences Limited, Annual General Meeting, Nov 11, 2022

Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial

Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer

Anatara Lifesciences Updates on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

Anatara Lifesciences Provides Clinical Trials Update

Anatara Lifesciences Limited Provides Clinical Trials Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

Anatara Lifesciences Limited Provides Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome

Anatara Lifesciences Provides This Update on Clinical Trial Activities

Insider recently sold AU$177k worth of stock

First half 2021 earnings released: AU$0.016 loss per share (vs AU$0.036 loss in 1H 2020)

Anatara Lifesciences Receives Ethics Approval to Start IBS Trial

Anatara Lifesciences Announces Successful Poultry Trial

Anatara Lifesciences Limited Announces Cessation of Tracie Elizabeth Ramsdale as Director

Anatara Lifesciences Limited Announces Retirement of Tracie Ramsdale as Non-Executive Director

Anatara Lifesciences Limited Auditor Raises 'Going Concern' Doubt

New 90-day high - AU$0.21

Shareholder Returns

Price Volatility

About the Company

Anatara Lifesciences Ltd Fundamentals Summary

0.0x

-7.7x

Earnings & Revenue